To investigate the epidemiology of Coccidioides immitis infection in persons returning to western Canada from C immitis endemic zones in southwestern United States. DESIGN: Review of C immitis serology requests from 1996. METHODS: Data were based on review of enzyme immunoassay and immunodiffusion results from 1993 to 1996 inclusive. Detailed information on clinical presentation, treatment and outcome of disease process was obtained through questionnaires and interviews with physicians who submitted Coccidioides serology requests in 1996. RESULTS: Positive serology for C immitis increased from 4.7% to 5.2% (between 1993 and 1995 inclusive) to 10.7% in 1996. Enzyme immunoassay for immunoglobulin G and/or immunoglobulin M or immunodiffusion was positive in 25 patients in 1996. The mean age of these patients was 62 years, and the predominant clinical presentation was pulmonary infiltrate with fever. All patients with positive serology were known to have travelled to central or southwestern Arizona or southern California. CONCLUSIONS: Travel to a defined coccidioidomycosis endemic zone presents a risk for the older traveller. Serology for C immitis supported the clinical, histological and microbiological diagnoses in patients who had travelled to this defined endemic zone.
C occidioidomycosis is caused by the dimorphic fungus Coccidioides immitis. Infection is often asymptomatic but may result in acute or chronic disease. Approximately 40% of persons exposed to this fungus develop mild to acute pulmonary disease; less than 1% develop serious disseminated infection.
The fungus is restricted to soil in the southwestern United States, west Texas and in selected areas of Central and South America (1) . Coccidioidomycosis in these endemic areas is usually sporadic, but outbreaks or increased incidence of infection have been noted following windstorms, earthquakes and unusually heavy rainfalls, all resulting in widespread landslides (2, 3) .
Since 1990, marked increases in recorded active cases of infection have been reported throughout the southwestern United States but particularly in Arizona (144% increase) and parts of California (4) (5) (6) . Reports from Morbidity Mortality Weekly Report have also highlighted cases that have occurred in areas where C immitis is not endemic (7) .
The National Centre for Mycology (NCM), Edmonton, Alberta, operates in conjunction with the Laboratory Centre for Disease Control, Ottawa, Ontario. The NCM receives samples of sera for serological analysis of fungal infections from all provinces in Canada with the exception of Quebec. Our observations from 1993 through 1995 indicated only sporadic serological evidence of exposure to C immitis in travellers returning from the United States. Almost all requests for C immitis serology are for patients who reside in western Canada, and an earlier report on coccidioidomycosis in Canada indicated that 94% of C immitis cases were identified from western Canada (8) . In 1996, we noticed a 100% increase in positive serology for C immitis in samples submitted to NCM. In the present study, we present clinical evidence to support serological evaluations of persons from western Canada who had travelled to the southwestern United States and returned with suspected C immitis infection.
METHODS

Enzyme immunoassay:
The Premier Coccidioides enzyme immunoassay (EIA) (Meridian Diagnostics, Inc, Ohio) was used as the screening test. This is a qualitative assay for the detection of immunoglobulin (Ig) M and IgG antibodies directed against the purified tube-precipitating and complement fixing antigens of C immitis in serum and cerebrospinal fluid. The test has a microwell configuration, and the procedure followed was that recommended by the manufacturer in the product insert. Immunodiffusion test: Immunodiffusion test (ID) (ImmunoMycologics, Inc, Oklahoma) was used as a supplementary test for all specimens giving positive and/or indeterminate results with EIA to establish definitive diagnostic criteria in the laboratory. The test was performed in accordance with the manufacturer's recommendations. Clinical data: Clinical information was acquired by sending a questionnaire to and requesting relevant diagnostic findings and symptomatology from the physicians of all patients with positive serology results. Information requested included patient demographics, clinical presentation and diagnosis, travel history, mycology culture results if available and performed in a laboratory other than NCM, types of specimens collected, biopsy and/or histological evidence of disease, use of any antifungals, and patient outcomes. Travel histories were available for all of these patients. Patients with negative serology but whose laboratory requests indicated that the patients had travelled to a Coccidioides endemic area also had clinical information collected using the same format as that for patients with positive serology. In cases with negative serology where there was no travel indicated on the requisition or when the travel indicated was to nonendemic areas such as Idaho or the southeastern United States, no additional clinical information was collected.
RESULTS
Seropositive cases:
Between 250 and 320 samples are received annually for C immitis serology at NCM. Statistics from 1993 through 1995 showed that 4.7% to 5.2% of samples each year were positive. The seropositive rate increased to 10.7% in 1996 (a 100% increase from that of the previous three years) without a significant change in the number of samples submitted. In 1996, a total of 25 patients had positive serology for C immitis. Serology results on 30 samples from these patients are summarized in Table 1 endemic area. Of the patients who had positive serology results, five had positive C immitis cultures, four were negative by culture and the remaining 16 had no cultures performed. Clinical histories were provided for all 25 patients, 13 males and 12 females with ages ranging from 38 to 81 years (mean 62 years). All patients either travelled to or spent winter months in central or southwestern Arizona, or southern California. The predominant clinical presentations reported were pulmonary infiltration or consolidation (14 patients), fever (12 patients), cough (eight patients), chest pain (five patients), pleural effusion (two patients) and pneumonia (two patients). Two patients had skin eruptions. Biopsy from one patient was positive for C immitis on histology and culture. Ten patients were treated with antifungal agents, of whom six were reported as having a favorable outcome, four continued therapy and two had excisional biopsies. All but one of the remaining patients had radiographic evidence suggestive of C immitis infection and were being followed clinically. One patient (patient 12) had no chest x-ray evidence of C immitis infection and was thought to have had a previous exposure. This patient was positive for IgG only by EIA. The following case presentations were typical of this group of patients. Case report 1: A 68-year-old male from western Canada who travels each winter to southern Arizona (patient 2) returned home in 1996 with a dry cough, fever, general malaise and weight loss. As reported by the attending physician, a chest xray revealed a mass in the left lower lobe of the lung. The differential diagnosis included malignancy and infection. A lung biopsy was collected for histology, and serum was submitted to the NCM for serology. Culture was not performed. The attending physician reported the lung biopsies positive for coccidioidomycosis. Serology was positive for IgM and IgG by EIA and positive for F antibody by ID. The patient was treated with oral fluconazole 400 mg daily for nine months. Clinical improvement was observed, although a chest x-ray at the end of treatment did not show complete resolution of the lung lesion. Case report 2: Four days after returning from a two-to threeweek vacation in Arizona, a 57-year-old female (patient 17) developed headache, malaise and anorexia. This was followed several days later by fever, chills, a nonproductive cough and Table 2 . The mean age (60 years) was approximately the same as the seropositive patients. The predominant clinical features differed in this group of patients. Cough and general malaise were more common. Only two patients were treated with antifungal agents. Diagnoses in this collection of patients were different. Incidental solitary pulmonary nodules were observed on chest x-rays of four patients who demonstrated no evidence of pulmonary disease. Only one patient had a diagnosis for which coccidioidomycosis was considered probable, but only chest x-ray evidence of a lung nodule was supportive of the diagnosis.
DISCUSSION
The increase in 1996 of the number of patients from western Canada with positive serology for C immitis is a sequela to natural environmental events that have occurred in southwestern United States in the previous few years. Windstorms, landslides, earthquakes and possibly fires in this part of the country provide a mechanism for disturbing the alkaline soil that naturally harbours arthroconidia of C immitis. Travellers to this arid endemic zone are, therefore, at greater risk of exposure to the fungus.
The three cases presented in detail illustrate several important features of C immitis infection that we observed in the entire group with positive serology. Patients with suspected coccidioidomycosis are older than 40 years (Table 1) . They may have repeated exposure by regular annual travel to the endemic zone, but shorter exposure may also result in acute infection. Resolution of symptoms may occur without specific therapy, but prolonged antifungal therapy may be required for clinical resolution. Residual evidence of exposure is often observed on chest x-ray long after clinical resolution of symptoms.
Serological investigations for coccidioidomycosis are justified in persons who present with a suspected pulmonary infection and a concomitant history of travel to a C immitisendemic area. Clinical histories and other diagnostic findings are also important to rule out other causes of pulmonary diseases such as those identified in Table 2 . Nonspecific entities such as fever, cough and general malaise are insufficient to confirm a diagnosis of Coccidioides infection in a traveller to an endemic area. In the sample from the seronegative group that was investigated by the same criteria as the seropositive group, only 15 of 31 patients had a chest x-ray, which may be more useful to establish a diagnosis. In four patients, radiographic evidence of solitary 'walled-off' lesions suggestive of Coccidioides exposure without serological correlation is of in- terest. We believe that the initial exposure to C immitis may invoke an asymptomatic IgM response, but once the developed spherule has been 'walled-off' by the host's inflammatory response, there is no further presentation of antigenic epitopes to elicit an antibody response. It is possible that C immitis exposure in these patients may have occurred in the distant past in the absence of other conditions that predisposed the patients to overt disease. Of the seropositive patients, 40% received antifungal therapy. Only two (6%) of the group with negative serology that we investigated received antifungal therapy once the results of the serology were known. A recent report suggested that relapse of infection may be more frequent in patients with higher complement-fixing antibody titres to C immitis (9) . It is possible in the patients included in this study that negative serology implied a lower degree of concern by physicians about the need to treat, particularly when the antifungal treatment course for coccidioidomycosis is long.
Our observations support a role for serology by EIA for IgM and IgG with ID for F antibody as an adjunct for the diagnosis of coccidioidomycosis in patients who have travelled to an endemic area. The EIA used in this study has been reported by others as a sensitive and specific test, particularly for IgM antibodies (10). The ID for IgG to F antigen is considered to have similar sensitivity to complement fixation, but different antibodies are detected. Patients with an initial negative ID result may demonstrate seroconversion to a positive ID if a follow-up specimen is submitted after an interval of three to four weeks (patient 8, Table 1 ). Previous reports have suggested that complement fixation, which is considered to be less sensitive than ID for IgG, may have useful prognostic value. High complement fixing titres reflect increased risk for extrapulmonary disease (11) . In this study, complement fixation testing was performed on paired sera from one patient only. The complement fixation test results were negative, ID was positive and the patient's infection did not spread beyond the respiratory tract.
CONCLUSIONS
Our results indicate that patients with C immitis positive serology increased by 100% in 1996 over the previous three years. Our laboratory methodology has remained the same throughout this period. The patients were attended by many physicians in many different locales, and there is no reason to suspect that physician practices changed during the period of study. If this were the case, we might have expected a significant increase in the number of requests for Coccidioides serology. Our data do not tell us if the patients in 1996 stayed longer in the endemic area, but many travellers go every year to the southwestern United States. It is possible that regular exposure over several years increases the likelihood of acquiring this fungus. However, our results support data from the United States that the true incidence of coccidioidomycosis has increased over the last few years. In 1996, we identified at least 25 new cases of C immitis infection; in one year, almost one-fifth the number reported in Canada over the previous 35 to 40 years (8) .
The Premier Coccidioides EIA screening test provided laboratory evidence supporting the diagnosis of C immitis infection in this nonendemic population. Physicians should consider the diagnosis of coccidioidomycosis in older patients who have travelled to defined endemic zones in the southwestern United States and who present with bronchopulmonary disease. Early recognition of IgM antibodies to C immitis by EIA will support the clinical diagnosis; however, negative serology by itself does not exclude a clinical diagnosis of coccidioidomycosis. Additional investigations including chest xray and skin testing can provide helpful evidence for other disease processes.
